Stocktoria

Cadrenal Therapeutics, Inc. CVKD

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2023-01-20

Cadrenal Therapeutics, Inc. statistics & valuation

Market cap$8.7M
P / B3.2×
Return on capital-491.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2022202320242025
Operating margin (%)
2022202320242025
Return on equity (%)
-108.60% -143.20% -483.30% 2022202320242025
Shares outstanding
8.2M 899465 1.8M 2.3M 2022202320242025
Net debt ($)
2022202320242025
Share buybacks ($)
2022202320242025
Return on assets (%)
-862.80% -98.10% -105.20% -305.90% 2022202320242025
Free cash flow margin (%)
2022202320242025
Debt / equity (×)
2022202320242025
EPS ($)
-$0.85 -$9.29 -$8.73 -$6.64 2022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022
Return on assets-305.9%-105.2%-98.1%-862.8%
Return on equity-483.3%-143.2%-108.6%121.0%
Current ratio2.723.7710.270.55

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.